Inovio Pharmaceuticals, Inc. INO NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

51/100

3/7 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Inovio Pharmaceuticals, Inc. (INO) has a negative trailing P/E of -6.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -16.78%, forward earnings yield 30.03%. PEG 0.05 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.05); analyst target implies upside (+440.5%).
Forward P/E 3.3 — analysts expect a return to profitability with estimated EPS of $0.33 for FY2028.
PEG Ratio 0.05 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Trailing Earnings Yield -16.78% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 30.03% as earnings recover.
Analyst consensus target $6.00 (+440.5% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

51/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

64/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

75/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — INO

Valuation Multiples

P/E (TTM)-6.0

Forward P/E3.3

PEG Ratio0.05

Forward PEG0.05

P/B Ratio21.01

P/S Ratio885.74

EV/EBITDA-0.3

Per Share Data

EPS (TTM)$-0.18

Forward EPS (Est.)$0.33

Book Value / Share$0.05

Revenue / Share$0.00

FCF / Share$-0.19

Yields & Fair Value

Earnings Yield-16.78%

Forward Earnings Yield30.03%

Dividend Yield0.00%

Analyst Target$6.00 (+440.5%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-82.5	-0.61	49.32	171.91	-
2017	-45.9	-6.63	28.46	95.99	0.56%
2018	-45.7	16.46	50.99	145.42	-
2019	-41.3	5.43	1,436.66	1,200.19	-
2020	-105.5	-10.24	38.08	2,369.48	-
2021	-42.3	-1.29	32.16	7,241.33	-
2022	-1.3	0.00	1.67	36.27	-
2023	-1.0	0.02	1.16	163.10	-
2024	-0.5	0.01	0.73	228.26	-
2025	-9.6	0.18	33.86	12,485.24	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-1.01	$35.37M	$-73.74M	-208.5%
2017	$-1.08	$42.22M	$-88.21M	-208.9%
2018	$-1.05	$30.48M	$-96.97M	-318.1%
2019	$-14.65	$4.11M	$-120.55M	-2931.8%
2020	$-16.64	$7.41M	$-215.09M	-2902.2%
2021	$-17.55	$1.77M	$-305.38M	-17207.1%
2022	$-14.47	$10.26M	$-287.66M	-2803.1%
2023	$-6.09	$832.01K	$-135.12M	-16239.9%
2024	$-3.95	$217.76K	$-107.25M	-49254.3%
2025	$-1.81	$65.34K	$-84.95M	-130000%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-1.21	$-1.56 – $-0.93	$10.88M	$733.46K – $30.45M	4
2027	$-0.53	$-1.04 – $-0.01	$68.4M	$44.25M – $92.55M	3
2028	$0.65	$0.06 – $1.11	$174.85M	$174.85M – $174.85M	3
2029	$1.09	$0.44 – $2.01	$235.3M	$126.7M – $387.83M	1
2030	$1.25	$0.50 – $2.31	$254.64M	$137.11M – $419.71M	1